Dr. Irmgard Resch
Abteilung Begutachtung Pharmakovigilanz
PSUR, PSUSA und EURD-Liste - ein Update
AGES Gespräch 13.6.2017
As of 13 June 2016, all periodic safety update reports (PSURs) for human medicines authorised in the European Union (EU) must be submitted to the PSUR repository.
The PSUR repository provides an important simplification for marketing authorisation holders allowing them to send all PSURs to a single recipient.
all PSUR submissions across Europe only via this channel AGES: no paper, CD-, e-mail-, CESP-submissions accepted for PSURs
PSUR repository Mandatory
• Go-live - 26 January 2015 • Pilot - 26 January 2015 – 10 February 2016 • Switch-on: 11 February – 12 June 2016 • Mandatory use: since 13 June 2016
Dr. Irmgard Resch 2
eSubmission over Gateway / Web Client, MAH should register to use the submission tools, existing eSubmission Gateway/Web Client users do not need to re-register. Submissions are made using an XML delivery file. The delivery files are used to provide required metadata allowing the EMA to process the submissions. The XML delivery file must be included within the submission package (i.e. in the relevant ZIP file).
New: User Guidance for submissions via eSubmission Gateway / Web Client using xml delivery files, EMA/346582/2016, 5 May 2017
http://esubmission.ema.europa.eu/gateway/Gateway%20user%20guide%20xml%20delivery%20files.pdf
PSUR repository New information
Dr. Irmgard Resch 3
The PSUR submission should include a cover letter containing a completed formatted table template to facilitate the registration of the submission.
This template should be completed in accordance with the published EURD list, where the procedure number is the combination of a unique ID and the applicable Data Lock Point (DLP) in YYYYMM format.
PSUR submission Cover letter
Dr. Irmgard Resch 4
PSUR submission Formatted table template
1* Applicant/MAH Name
2* Customer Account Number xxxx (only for WS, IG and MAA)
3* Customer Reference / Purchase Order Number
4 INN / Active substance/ATC Code
5 Product Name of centrally authorised medicinal product(s)
5.1* Nationally Authorised Product(s) Please refer to Annex I
6* Product Number or
Procedure Number or
PSUSA (PSUR Single Assessment)
Non-EU single assessment
PSUR Period Covered (for both PSUSA and Non-EU procedures)
H XXXX or
EMEA/H/C/XXXX / type / or
PSUSA/000XXXXX/yyyymm
National Marketing Authorisation No
-
7* Submission Type (Please select)
7.1* Submission Unit Type
7.2* Grouping (more then one scope) Yes
7.3* Submission Description
8* Please provide the name(s) of any centrally authorised medicinal product for which the same change(s) are
being applied for outside of this procedure
Product name and number:
9* RMP included in this submission: Yes No RMP version N.
10* eCTD sequence 00xx Related sequence 00xx
Dr. Irmgard Resch 5
PSUR submission Formatted table template
11* Contact Persons’ details
(include email address)
A) Regarding the content of the submission:
B) Regarding eCTD technical questions:
To be completed as applicable:
12*
For PAM submissions or in case a
procedure such as a variation
addresses an outstanding PAM:
PAM type
PAM area
PAM data
PAM originating from:
(If this submission is related to a previous PAM, please specify previous PAM number)
Brief description of the PAM including number (if known) and refence to the procedure, date and Committee the PAM was requested:
EPITT Number (For SDA submissions only)
I confirm that the submission does not fall under any categories of the Classification guidance on variations and that the data
submitted do not influence the benefit-risk balance and therefore do not require taking further regulatory action on the marketing
authorisation.
I confirm that the submission does not include a final study report (except P46 applications)
Dr. Irmgard Resch 6
PSUR submission Formatted table template
13* For submissions of final study reports in the
context of a variation
14 For P46 submissions study title and number stand alone study(ies).
study title and number part of a clinical development program. The application
consisting of the full relevant data package (i.e. containing several studies) is expected to be
submitted by MM/YY. A line listing of all the concerned studies is attached for your
consideration.
15* Submission in accordance to Art. 8 of Paediatric
Regulation (EC) No 1901/2006 of 12/12/2006
Is your product is protected by a Supplementary Protection Certificate (SPC) or a patent that
qualifies for a SPC?
Yes No
16 Confirmation that the clinical reports submitted
for scientific evaluation are the same as those
submitted for publication, in the Redaction
Proposal and Final Redacted Versions, except for
the redactions
Included
Yes
Dr. Irmgard Resch 7
Medicinal products authorised under Articles 10(1), 10a, 14 or 16a of Directive 2001/83/EC are exempted from routine submission of PSURs unless otherwise specified in the MA or required through the EURD list. National competent authorities can also request PSURs for generic medicinal products at any time on the grounds detailed in Article 107c (2) of the Directive.
MAHs of such medicinal products should use alternative mechanisms (signal management etc.) to communicate relevant new safety information to regulatory authorities (see GVP module VI and IX).
PSUR submission Special cases
Dr. Irmgard Resch 8
If fixed dose combination not listed in the EURD list, PSURs submitted as specified in the conditions of the MA for the combination product (if any), or otherwise according to the standard submission cycle unless the combination medicinal product falls within the categories of medicinal products exempted from the obligation to submit PSURs.
MAHs should submit PSURs once a medicinal product is authorised in the EU, regardless of its marketing status.
PSUR submission Special cases
Dr. Irmgard Resch 9
Non-interventional PASS study protocols and reports should not be submitted to the PSUR Repository. The PASS 107 submissions should be submitted to EMA using eSubmission Gateway / Web Client using the relevant submission type. PASS 107 submissions for centrally authorised products are available to the NCAs via the Common Repository. For more information on the PASS 107 submissions please see EMA regulatory Post-Authorisation Guidance.
Link: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000090.jsp
PSUR submission Special cases
Dr. Irmgard Resch 10
If a parallel importer receives a notification of an adverse drug reaction from a patient, a doctor or any other source, the parallel importer should inform this person that the adverse drug reactions should be reported directly to the MAH of the medicinal product concerned. The parallel importer should also inform the MAH immediately.
Only MAHs are required to submit PSURs as per the provisions of Article 107b of Directive 2001/83/EC and Article 28(2) of Regulation (EC) No 726/2004. Parallel importers do not qualify as MAHs, and therefore they are not subject to the obligation to submit PSURs.
PSUR submission Special cases
Dr. Irmgard Resch 11
A risk management plan (RMP) update can be submitted with a PSUR for single centrally authorised medicinal product (CAP) or a mixture of CAPs belonging to the same global marketing authorisation when the changes to the RMP are a direct result of data presented in the PSUR. In this case no stand-alone RMP variation is necessary.
If the above does not apply, the updated RMP should be submitted as a stand-alone variation.
PSUR submission Additional RMP
Dr. Irmgard Resch 12
Literatur should not only be presented in the PSUR, but a comment / conclusion of the MAH on the benefit risk should be added
MAH should not only describe important case reports, but draw conclusions and justify them as well.
The Reference Safety Information (RSI) should be in English When the RSI is added, the MAH should make a statement (in
the regional part of the PSUR) if/that the information is available in the local SmPCs as well
Fatal cases which are mentioned in the signal section and are not commented, are trigger for questions by LMS
PSUR submission Hints on the quality of PSURs
Dr. Irmgard Resch 13
If you are experiencing issues with the XML delivery file screen, PSUR repository interface or eSubmission Gateway/Web Client, contact the EMA via https://servicedesk.ema.europa.eu/ This portal replaces [email protected] [email protected], [email protected]. PSUR submission for nationally authorised products: [email protected]
PSUR repository Contacts
Dr. Irmgard Resch 14
For queries on fees and QPPV advice notes (please refer to question “What fee do I have to pay?”), you can contact the EMA using the designated EMA Fees Query Form available on the Pharmacovigilance fees: questions and answers webpage.
The Agency aims to respond to your query within 5 working days. Information whether query refers to NAP or CAP, the procedure number of the PSUSA, the name of the product and the name of the active substance/combination of active substances.
keep ‘Article 57 database’ updated (MA withdrawn etc.)
PSUR submission Fees
Dr. Irmgard Resch 15
In addition to the „active“ EURD list there is information available on removed entries:
EURD list Update
Active substances and combinations of active substances removed from the EURD list Month removed Comments
amyleine / chlorhexidine Apr 17 Entry to be removed since no products have been identified containing this active substance combination.
bacitracin / chlorhexidine Apr 17 Entry to be removed since no products have been identified containing this active substance combination.
bendroflumethiazide Apr 17 Removal from EURD list: New entry: "bendroflumethiazide, bendroflumethiazide / potassium chloride" to be followed (PSUSA/00010583)
benzalkonium chloride / chlorhexidine dihydrochloride / isopropyl myristate / paraffin liquid Apr 17 Entry to be removed from the EURD list since products in only one MS identified containing this combination of
active substances.
collagen Apr 17 Entry to be removed since no products have been identified containing this active substance combination.
collagenase clostridium histolyticum (all indications except for treatment of Dupuytren’s contracture and Peyronie’s disease) Apr 17 Entry to be removed since no products have been identified containing this active substance combination.
Dr. Irmgard Resch 16
For information on how to submit requests for amendments of the EURD list or any other questions related to the EURD list, please refer to the ‘Introductory cover note to the List of European Union reference dates and frequency of submission of Periodic Safety Update Reports (24 October 2016, EMA/606369/2012 Rev.15)
EURD list Further information
Dr. Irmgard Resch 17
History of pharmacovigilance system inspections Worldwide marketing approval status Actions taken for safety reasons during the period Significant changes to the SmPC Estimated exposure and used patterns Data in summary tabulations Summaries of significant safety and efficacy findings from
clinical trials and non-interventional studies during the period covered by the renewal
Literature Risk evaluation
Renewal ACO structure
Dr. Irmgard Resch 18
Benefit evaluation Benefit/risk balance Late-breaking information MAHs are advised to consider the GVP Module VII on PSURs as guidance for preparation of the ACO. Link: CMDh Best practice guide on the processing of renewals in the mutual recognition and decentralised procedures (CMDh/004/2005/Rev.14) http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/procedural_guidance/Renewal/CMDh_004_2005_Rev14_2016_02_clean.pdf
Renewal ACO structure
Dr. Irmgard Resch 19
The Clinical Expert should: Confirm that no new clinical data are available which change or result
in a new benefit-risk balance evaluation.
Confirm that the product can be safely renewed at the end of a 5-year period for an unlimited period.
Confirm that the authorities have been kept informed of any additional data significant for the assessment of the benefit-risk balance of the product concerned.
Confirm that the product information is up to date with the current scientific knowledge including the conclusions of the assessments and the recommendations made publicly available on the European medicines web-portal.
Renewal Addendum to Clinical Overview
Dr. Irmgard Resch 20
AT=RMS: ein „Addendum zum clinical overview“ ist vorzulegen. AT=CMS: ein „Addendum zum clinical overview“ ist vorerst nur vorzulegen, wenn es vom Reference Member State gefordert wird.
Nationally authorised products:
ACO required for all products (also generic, well established use, traditional herbal and homeopathic authorisations)
The “Addendum to the clinical overview “ should cover the period from the date of approval to the date of submission of the renewal.
Apothekeneigene Zulassungen so far exempted from PSUR submission.
Renewal ACO Requirements for AT
Dr. Irmgard Resch 21
Periodic safety update: questions and answers http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/q_and_a/q_and_a_detail_000041.jsp&mid=WC0b01ac0580023e7d further important links
eSubmission / PSUR repository http://esubmission.ema.europa.eu/psur/psur_repository.html
BASG Homepage Pharmakovigilanz FAQ http://www.basg.gv.at/pharmakovigilanz/faq-pharmakovigilanz/ Veterinary PSURs: Q&A: Periodic Safety Update Report http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/q_and_a/q_and_a_detail_000064.jsp
PSURs Further information
Dr. Irmgard Resch 22
Dr. Irmgard Resch 23
Frage von Pharmig: Auf der BASG-Website werden unter eServices >> Zulassung und Lifecycle von Arzneispezialitäten >> Laufende Abringen nationale PSURs (Non-EU-SA), welche über das PSUR-Repository eingereicht werden, als „nationales PSUR Gutachten“ mit einer Verfahrensnummer angeführt. Wie lange dauert von Seiten der AGES der Eintrag auf dieser Seite? Oder anders gefragt: Ab welcher Dauer nach Einreichung und Nicht-Erscheinen in eServices/Laufende Anbringen kann man damit rechnen, dass die Einreichung/Übertragung möglicherweise nicht geklappt hat? Ab wann kann/soll man nachfragen?
Hintergrund: Eine Woche nach unserer Einreichung über das PSUR-Repository gibt es noch keinen Eintrag in den eServices.
PSUR submission Question
Dr. Irmgard Resch 24
Bearbeitung erfolgt meist innerhalb einer Woche bitte nachfragen, wenn nach einer Woche Bestätigung noch
nicht in eServices aufscheint E-Mail an: [email protected] Mögliche Fehlerquellen: -- falsches Land angeklickt durch MAH -- Häkchen vergessen durch AGES
PSUR submission eServices
Dr. Irmgard Resch 25
Vielen Dank
für die Aufmerksamkeit!
BASG - Bundesamt für Sicherheit im Gesundheitswesen
www.basg.gv.at
Traisengasse 5 1200 Wien
Gutachterin Pharmakovigilanz
T +43(0) 50555-36260
Mag. Dr. Irmgard Resch